Loading
A simple clinical score decides between two immunotherapies together or one immunotherapy with a targeted pill.
Intermediate/poor risk: nivolumab-ipilimumab (durable remissions, treatment-free survival) or an IO-TKI doublet (higher response rate, less primary progression). Favourable risk: IO-TKI doublet or TKI alone, since IO-IO shows no OS gain there. Sarcomatoid features favour IO-based therapy regardless of risk.
Shares Sarcomatoid differentiation (RCC), IMDC risk groups (favourable / intermediate / poor), Ipilimumab, Renal cell carcinoma.
Shares IMDC risk groups (favourable / intermediate / poor), Lenvatinib, Renal cell carcinoma, Pembrolizumab.
Shares Axitinib, Lenvatinib, Pembrolizumab, Immune checkpoint inhibitors.
Shares Cabozantinib, Ipilimumab, Renal cell carcinoma, Nivolumab.
Shares IMDC risk groups (favourable / intermediate / poor), Axitinib, Renal cell carcinoma, Pembrolizumab.
Shares Axitinib, Renal cell carcinoma, Pembrolizumab, Small-molecule kinase inhibitors.
Shares Cabozantinib, Lenvatinib, Nivolumab, Small-molecule kinase inhibitors.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/